{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'Table 2', 'Schedule of Assessments for Patients who Discontinued Early from Randomized Treatment', 'Safety and Disease Severity Follow-up', 'Assessment', 'End of Study / Early Trial Discontinuation', 'Unscheduled', 'Period', 'Visit', 'FUn', 'EoS/ED', 'UNSd', 'Trial Day (Visit Window)', 'Z+30 to 182 (=3)', '182+3', 'Disease severity assessment', 'MG-ADLe', 'X', 'X', 'X', 'QMGe', 'X', 'X', 'X', 'Safety follow-up', 'Urine pregnancy test', 'X', 'X', 'X', 'Concomitant/rescue therapy', 'X', 'Adverse events', 'X', 'ED = Early Discontinuation; EoS = End of Study; EoT = End of Treatment; FU = Follow-up; MG-ADL = Myasthenia Gravis Activities of Daily Living; QMG = Quantitative Myasthenia', 'Gravis; UNS = Unscheduled; Z = last visit performed as per Table 1.', 'This schedule of assessments (SoA) is to be followed for patients who discontinue early from randomized treatment. Patients who discontinue early from randomized treatment within a', 'Treatment Cycle will have to complete the EoT assessments and complete the remaining visits in the current Treatment Cycle, prior to entering the Safety and Disease Severity Follow-up', 'period as per this SoA. These patients will not receive any further IMP administration during the trial. Patients who discontinue early from randomized treatment in the Inter Treatment Cycle', '(ITC) period will have to complete the EoT assessments and then continue into the Safety and Disease Severity Follow-up period.', 'b', 'After the patient completed either the current Treatment Cycle or the EoT assessments of the current ITC visit if decision was made in the ITC period, the patient should return every month', 'for the Safety and Disease Severity Follow-up visits until Day 182 as per this SoA.', 'For patients who discontinue early from randomized treatment, only a limited number of assessments need to be performed at the EoS/ED visit.', 'd', 'An unscheduled (UNS) visit can be on request of the patient or the Investigator. During the UNS visit, additional assessments can be performed at the discretion of the Investigator,', 'depending on the reason for the UNS visit.', 'e', 'Disease severity assessments should be performed prior to any other trial-specific assessment in the following sequence: 1) MG-ADL, 2) QMG. Acetylcholinesterase inhibitors must be', 'halted for at least 12 hours before the QMG assessment (consistent with the revised manual for the QMG test as recommended by the Myasthenia Gravis Foundation of America Inc', '[MGFA]).', 'f', 'A urine pregnancy test will be performed only for women of childbearing potential (see DEFINITION OF TERMS).', 'argenx BVBA', 'Confidential', 'Page 31 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'Figure 1', 'Trial Design', 'EoS', '26 weeks', '(Day 182)', 'TREATMENT CYCLE SEQUENCE*', 'Treatment Cycle [TC1]', 'Inter Treatment Cycle period*', 'Treatment Cycle(s) [TC,]', '(weekly visits)', '(every 2 weeks visits)', '(weekly visits)', 'Placebo', 'Placebo', 'SoC', 'Screening', 'ARGX-113', 'ARGX-113', '(10 mg/kg)', '(10 mg/kg)', 'TC(number}', 'SEB;TC1B', 'TC,B', 'Prim. EP', 'Visits', 'TC1', 'V1', 'V2', 'V3', 'V4', 'V5', 'V6', 'V7', 'V8', 'V9', 'ITC1V1', 'ITC,Vn', 'TCn', 'V1', 'V2', 'V3', 'V4', 'V5', 'V6', 'V7', 'V8', 'V9', 'Study Day* (D1) (D8) (D15) (D22) (D29) (D36) (D43) (D50) (D57)', '(D71)', '(Dx)', '(Dx)', '(Dx)', '(Dx)', '(Dx)', '(Dx)', '(Dx)', '(Dx)', '(Dx)', '(Dx)', '*', '+', '1', 'day for Treatment Cycle visits and + 2 days; for Inter Treatment Cycle visits; ** Interval time may vary from patient to patient; *** May be repeated as many times as needed during the time frame of the trial. Last', 'Treatment Cycle should not start later than on Day 127 of the trial.', 'EoS = End of Study; Prim. EP = Primary Endpoint; ITC = Inter Treatment Cycle; SEB = Study Entry Baseline; SoC = Standard of Care; TC = Treatment Cycle; TC,B = Treatment Cycle [number] Baseline', 'argenx BVBA', 'Confidential', 'Page 32 of 110']\n\n###\n\n", "completion": "END"}